Nkarta
Develops NKX019-led CAR NK therapies for B-cell autoimmune diseases.
$2.80
After-hours close+0.04 (+1.45%)
At close$2.76(+0.36%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.40 | — | — |
| Aug 2026 | −$0.36 | −$0.54 | −49.9% |
| Aug 2026 | −$0.36 | −$0.54 | −49.9% |
| May 2026 | −$0.39 | −$0.37 | +5.1% |
| Mar 2026 | −$0.32 | −$0.37 | −15.6% |
The latest year is open to everyone — the 27 quarters behind it read with an account. Sign in | |||
| Nov 2025 | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| Jul 2020 | |||
| Dec 2019 | |||
| Sep 2019 | |||
| Jun 2019 | |||
| Mar 2019 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 10, 2026 | −$0.40 | — | — | — | — | — |
| Aug 11, 2026 | −$0.36 | −$0.54 | −49.9% | — | — | — |
| Aug 10, 2026 | −$0.36 | −$0.54 | −49.9% | — | — | — |
| May 12, 2026 | −$0.39 | −$0.37 | +5.1% | — | — | — |
| Mar 25, 2026 | −$0.32 | −$0.37 | −15.6% | — | — | — |
The latest year is open to everyone — the 27 quarters behind it read with an account. Sign in | ||||||
| Nov 10, 2025 | ||||||
| Aug 12, 2025 | ||||||
| May 14, 2025 | ||||||
| Mar 26, 2025 | ||||||
| Nov 7, 2024 | ||||||
| Aug 13, 2024 | ||||||
| May 9, 2024 | ||||||
| Mar 21, 2024 | ||||||
| Nov 9, 2023 | ||||||
| Aug 10, 2023 | ||||||
| May 11, 2023 | ||||||
| Mar 16, 2023 | ||||||
| Nov 9, 2022 | ||||||
| Aug 11, 2022 | ||||||
| May 12, 2022 | ||||||
| Mar 17, 2022 | ||||||
| Nov 10, 2021 | ||||||
| Aug 12, 2021 | ||||||
| May 13, 2021 | ||||||
| Mar 25, 2021 | ||||||
| Nov 12, 2020 | ||||||
| Aug 20, 2020 | ||||||
| Jul 13, 2020 | ||||||
| Dec 31, 2019 | ||||||
| Sep 30, 2019 | ||||||
| Jun 30, 2019 | ||||||
| Mar 31, 2019 | ||||||